Elsevier

Surgery

Volume 118, Issue 4, October 1995, Pages 711-715
Surgery

Management considerations in Hürthle cell carcinoma*

https://doi.org/10.1016/S0039-6060(05)80039-XGet rights and content

Background. Hürthle cell tumors still pose issues concerning diagnosis and management.

Methods. From 1984 to 1993 forty-seven patients underwent thyroidectomy, and they were diagnosed after operation to have presumptive Hürthle cell tumors. The surgical pathologic findings were reviewed. In the neoplastic group the chart was reviewed for clinical features and outcome.

Results. Thirty-one patients had nonneoplastic Hürthle cell nodules. Eleven (69%) of the 16 tumors were malignant affecting 11 women and five men ranging in age from 22 to 86 years. Two patients died of cancer for a 18% rate; one patient is alive with disease. Operations were uncomplicated. Factors for adverse outcome include tumor size greater than 4 cm, woman older than 60 years of age, and complete capsular invasion on surgical pathologic findings.

Conclusions. Fine-needle aspiration biopsy demonstration of Hürthle cell lesion is an indication for operation, providing Hashimoto's thyroiditis is excluded. Our surgical practice (I.B.R.) is to perform total thyroidectomy for all Hürthle cell neoplasms, as well as jugular node sampling and adjuvant radioiodine for cancer. Stringent histologic interpretation is possible and necessary for true appreciation of Hürthle cell tumor incidence and behavior. Cancer mortality of 18% is greater than the rate (2%) of our well-differentiated thyroid cancer group.

References (23)

  • TollefsenHR et al.

    Hürthle cell cancer of the thyroid

    Am J Surg

    (1975)
  • WatsonR et al.

    Invasive Hürthle cell carcinoma of the thyroid

    Mayo Clin Proc

    (1984)
  • McHenryCR et al.

    Prospective management of nodal metastases in differentiated thyroid cancer

    Am J Surg

    (1991)
  • RoedigerWEW

    The oxyphil and C cells of the human thyroid gland

    Cancer

    (1975)
  • MishnikiYY et al.

    Hürthle cell tumor arising in the mediastinal ectopic thyroid and diagnosed by fine needle aspiration: light microscopic and ultrastructural features

    Acta Cytol

    (1983)
  • Sobrinho-SimõesMA et al.

    Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study

    Ultrastruct Pathol

    (1985)
  • HürthleK

    Beitrage zur kenntnis de sekretionsvorganges in der schilddruse

    Arch F D Ges physiol

    (1894)
  • SchafferJ

    Beitrage zur Histologi menschlicher Organe: IV, Zunge, V, Mundhohle-Schlundkopf, VI, Oesophagus, VII, Cardia

    Sitzungsb d k Akad d Wissensch Mathnaturw Cl Wein

    (1897)
  • ChangA et al.

    Oncocytes, oncocytosis and oncolytic tumors

    Pathology Journal

    (1992)
  • TalliniG et al.

    Oncolytic neoplasms of the thyroid gland

    Acta Pathologica Japonica

    (1992)
  • ThompsonNW et al.

    Hürthle cell lesions of the thyroid gland

    Surg Gynecol Obstet

    (1974)
  • Cited by (52)

    • Hürthle Cell Tumors of the Thyroid

      2021, Surgery of the Thyroid and Parathyroid Glands
    • Surgeon-performed ultrasound predictors of malignancy in patients with Hü rthle cell neoplasms of the thyroid

      2013, Journal of Surgical Research
      Citation Excerpt :

      Hyperplastic nodules accounted for 30% of all patients with HCN. Other studies have reported the incidence of such nonneoplastic nodules from 9% to 66% [22,23]. Furthermore, in this study, the incidence of carcinoma in patients with HCN was 35%, which falls within the 14%–67% incidence range of malignancy reported by other investigators [11,12].

    • Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging

      2011, Seminars in Nuclear Medicine
      Citation Excerpt :

      Hürthle cell carcinoma was initially considered a variant of FTC; however, it shows a different oncogenic expression profile than FTC and is therefore now recognized as distinct clinicopathologic entity. It is an uncommon and occasionally aggressive differentiated thyroid malignancy,45 particularly when the primary tumor is widely invasive.4,46 Approximately 3.6% of thyroid cancers are of the Hürthle cell subtype.47

    • Positron Emission Tomography and Thyroid Cancer

      2007, PET Clinics
      Citation Excerpt :

      FDG-PET is preferred over radioiodine when the tumor cells are known to have low iodine uptake, such as in Hurtle-cell and undifferentiated (anaplastic) thyroid tumors. Hurtle-cell carcinoma has a worse prognosis, compared with papillary and follicular thyroid cancers, and presents unique clinical features, such as higher incidence of distant metastasis and a relatively aggressive clinical course.59–61 The patients with Hurtle-cell thyroid carcinoma are usually monitored with sequential serum Tg measurements, because more than 80% of the patients have noniodine-avid tumor and the clinical utility of radioiodine is limited in this population.

    View all citing articles on Scopus
    *

    Presented at the Fifty-second Annual Meeting of the Central Surgical Association, Cleveland, Ohio, March 9–11, 1995.

    View full text